NCT04593394

Brief Summary

The first part will be a comparative cross-sectional study to identify the frequency of ILO and other comorbidites among participants with asthma compared to a group of reference subjects without asthma, matched for age- and gender and race. The second part will be a longitudinally observational study study following participants for one year after the cross-sectional study. The Maat-scores ILO-symptoms and asthma-outcomes longitudinally will be evaluated, .

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
116

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Nov 2020

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 13, 2020

Completed
7 days until next milestone

First Posted

Study publicly available on registry

October 20, 2020

Completed
12 days until next milestone

Study Start

First participant enrolled

November 1, 2020

Completed
3.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2024

Completed
Last Updated

November 21, 2025

Status Verified

May 1, 2025

Enrollment Period

3.9 years

First QC Date

October 13, 2020

Last Update Submit

November 18, 2025

Conditions

Keywords

Inducible laryngeal dysfunction, Severe asthma,

Outcome Measures

Primary Outcomes (2)

  • Prevalence of ILO in the participants

    Continues during exercise(CLE)-test score at 2 or more at glottis or supraglottic level (Score range 0 minimum -3 maximum) 3 is full closure, 0 i open.

    One year

  • Changes in continues during exercise (CLE-)-test score

    The absolute change from baseline CLE-score (Score range 0 minimum -3 maximum). 3 is full closure in larynx, 0 is open.

    One year

Secondary Outcomes (4)

  • The prevalence of OSA in asthma patients with ILO.

    One year

  • Changes in asthma-controll score (ACT)

    One year

  • Number of asthma-exercabations

    One year

  • Changes in mini-Asthma quality of life (m-AQLQ)

    One year

Study Arms (3)

Severe asthma

Gina-guidlines treatment-step 5

Diagnostic Test: Continous laryngoscopy exercise testDiagnostic Test: Overnight respiratory polygraphy

Mild-moderate asthma

Gina-guidlines treatment-step 1-4

Diagnostic Test: Continous laryngoscopy exercise testDiagnostic Test: Overnight respiratory polygraphy

Subjects without asthma

Matches control-group without asthma

Diagnostic Test: Continous laryngoscopy exercise testDiagnostic Test: Overnight respiratory polygraphy

Interventions

Participants walks on a tredmill with a a flexible naso-laryngoscope in the larynx allowing visulasion of the larynx and obstructions in the larynx at the epiglottic og glottic levels are scored

Mild-moderate asthmaSevere asthmaSubjects without asthma

Overnight respiratory polygraphy is a continuous recording of nasal airflow, thoracic and abdominal movements, heart rate and oxygen saturation during the night used to detected sleep apnoea

Mild-moderate asthmaSevere asthmaSubjects without asthma

Eligibility Criteria

Age18 Years - 70 Years
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

The sample size of the cohort with severe asthma will be: All patients with severe asthma followed in our clinic for severe asthma estimated to be around 80 participants, of them, we hope to recruit at least 40 to perform the CLE-test, and we plan to recruit 40 participants with mild asthma and 40 age- and gender matched control subjects without asthma

You may qualify if:

  • Patients with severe asthma (GINA 5)
  • Patients with mild-moderate well-treated asthma (GINA step 1-4)
  • Agroup of age- and gender matched control subjects without asthma also aged 18- 70.
  • The patients must have had a stable disease the last one month before performing the CLE-test

You may not qualify if:

  • No have underlying neurologic disease.
  • No known cancer in the lung-head-neck
  • No known vocal cord pathology.
  • No history of life-threatening asthma required hospitalization.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Haukeland University Hospital

Bergen, 5021, Norway

Location

Related Publications (1)

  • Rogde AJ, Lehmann S, Halvorsen T, Clemm HH, Roksund OD, Hufthammer KO, Kvidaland HK, Vollsaeter M, Andersen TM. Prevalence and impact of exercise-induced laryngeal obstruction in asthma: a study protocol for a cross-sectional and longitudinal study. BMJ Open. 2023 Jun 16;13(6):e071159. doi: 10.1136/bmjopen-2022-071159.

MeSH Terms

Conditions

Vocal Cord DysfunctionAsthma

Condition Hierarchy (Ancestors)

Laryngeal DiseasesRespiratory Tract DiseasesRespiration DisordersOtorhinolaryngologic DiseasesBronchial DiseasesLung Diseases, ObstructiveLung DiseasesRespiratory HypersensitivityHypersensitivity, ImmediateHypersensitivityImmune System Diseases

Study Officials

  • Sverre Lehmann, PhD

    Haukeland University Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 13, 2020

First Posted

October 20, 2020

Study Start

November 1, 2020

Primary Completion

October 1, 2024

Study Completion

October 1, 2024

Last Updated

November 21, 2025

Record last verified: 2025-05

Locations